GELS
Gelteq Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$0.43
−3.50%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.9%
- EBITDA
- -93.5%
- EBIT
- -86.5%
- Net income
- -87.4%
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025